Alnylam Pharmaceuticals
ALNY
185 hedge funds and large institutions have $4.6B invested in Alnylam Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 62 increasing their positions, 69 reducing their positions, and 26 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 3 → 9 (+6)
25% more capital invested
Capital invested by funds: $3.68B → $4.6B (+$922M)
1% more call options, than puts
Call options by funds: $49.7M | Put options by funds: $49M
4% less funds holding
Funds holding: 193 → 185 (-8)
10% less repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 69
19% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 26
Top Buyers
Top Sellers
| 1 |
Norges Bank
Oslo,
Norway
|
-$32.8M |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$25M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$17.9M |
| 4 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
-$14.9M |
| 5 |
CCI
Columbus Circle Investors
|
-$9.65M |
ALNY Hedge Fund Activity: Q3 2014 in Review
185 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q3 2014, worth a combined $4.6B — up 25% from $3.68B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of ALNY and 21 opened new positions — a net loss of 5 holders — while 69 trimmed existing stakes and 62 added.
The largest buyer was 12 West Capital Management, opening a new position worth an estimated $42M. The largest seller was Norges Bank, cutting an estimated $32.8M.
- 185 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q3 2014, down from 193 in Q2 2014.
- Funds reported $4.6B of Alnylam Pharmaceuticals stock for Q3 2014, up 25% quarter-over-quarter.
- 21 funds opened new Alnylam Pharmaceuticals positions in Q3 2014 and 26 closed out, a net change of -5 holders.
- The largest Alnylam Pharmaceuticals buyer in Q3 2014 was 12 West Capital Management, an estimated $42M added.
- The largest Alnylam Pharmaceuticals seller in Q3 2014 was Norges Bank, an estimated $32.8M sold.
Based on aggregated 13F filings for Q3 2014.